Lv41
520 积分 2021-02-24 加入
A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma
1小时前
待确认
Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype
1小时前
待确认
Upfront VIP-reinforced-ABVD (VIPrABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma.Results of the randomized phase III trial GOELAMS-LTP95
5个月前
已完结
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study
5个月前
已完结
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
6个月前
已完结
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
6个月前
已完结
International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
6个月前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
6个月前
已完结
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
6个月前
已完结
Outcome of peripheral T-cell lymphoma in first complete remission: a DanishSwedish population-based study
6个月前
已完结
皖公网安备34019202002308
